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Background
The canarypox vector ALVAC-HIV, together with the HIV gp120 envelope, has protected 31.2% of Thai heterosexual individuals from HIV acquisition in the RV144 HIV vaccine trial. This outcome was unexpected, given the limited ability of the ALVAC-HIV vaccine component to induce CD8+T-cell responses, and of the HIVgp120 envelope to elicit broad neutralizing antibodies.
Methods
We vaccinated macaques with an immunization regimen that mimics the RV144 trial and exposed them to a mucosal dose of SIV mac251 that transmits few virus variants, similar to HIV transmission to humans.
Results
Vaccination induced anti-envelope antibodies, modest CD4+ and CD8+ T-cell responses. One third of the vaccinated macaques were protected from SIV mac251 acquisition, whereas the remaining infected vaccinees progressed to disease. Vaccine induced SIV mac251 specific T-and Bcell responses were not different in protected or infected animals. The sera of the animals protected had higher avidity antibodies to the gp120 envelope protein, recognized the variable envelope region V2, and reduced SIVmac251 infectivity in cells that express high level of α4β7, suggesting a functional role to antibodies to V2.
Conclusion
The SIV mac251 infection macaque faithfully reproduces results in humans, and is instrumental in the development of more efficacious vaccines for HIV. 
